Alpha-1 antitrypsin deficiency (AATD) Augmentation Therapy Market to Reach US$ 1,959.8 Mn, boosted by Newer Product Marketing Strategies by Leading Companies Forecast 2026

Global Alpha-1 antitrypsindeficiency (AATD) Augmentation Therapy Market to Reach US$ 1,959.8 Mn Boosted by Newer Product Marketing Strategies by Leading Companies, says Fortune Business Insight. The advent of numerous awareness programs for AATD is boosting the global AATD augmentation therapy market. According to a report published by Fortune Business Insights, titled “Alpha-1 antitrypsin
deficiency (AATD) Augmentation Therapy Market: Global Market Analysis, Insights and Forecast, 2019-2026,” the market valuation is likely to increase from US$ 1,115.5 Mn in 2018 to US$ 1,959.8 Mn by the end of 2026. The market is likely to expand due to change in approaches of AATD augmentation therapy and in doing so, it will exhibit a CAGR of 5.9%.

In 2018, Grifols introduced ‘AlfaCare’, aimed at providing comprehensive training and support program for AATD patients. Capitalizing on the commercial success of its brand ‘Prolastin C’, Grifols is likely to strengthen its market position during the forecast period. Backed by a strong market portfolio, Grifols accounted for the highest market share in 2018 and it is likely to dominate the market through the forecast period. 

The global AATD augmentation therapy market is consolidated in nature as only four companies account for the major share. Besides Grifols, S.A., Kamada Ltd, Shire Plc (Baxalta), and CSL Limited have made significant contributions towards growth of this market. Currently, around 80 new and existing molecules that include inhalation therapy are being tested in clinical trial for AATD. Boosted by this factor, the market may witness an influx of entrants during the forecast period. The aforementioned factors are major indications of growth of this market in the period of 2019-2026.

Prolastin C to Emerge as the Leading Product Type  

Prolastin C manufactured by Grifols, S.A. is considered as the most widely used product in augmentation therapy for AATD. In terms of value, Prolastin C accounted for 63.1% share in the market in 2018. The product is expected to maintain dominance through the forecast period. Besides Prolastin C, there are some other product types that have been adopted widely. The recent approval ‘Respreeza’ in Europe and Asia has fueled its demand in these regions. In 2016, Kamada Ltd and Shire plc announced the US FDA approval of expanded label for Glassia, making it the first self-infused treatment for adults with emphysema due to severe AATD. Therefore, increasing regulatory approvals for various products are likely to boost the global AATD augmentation therapy market in the forecast period.

Market in Asia Pacific to Exhibit Highest CAGR

Active government participation in prevention and control of genetic disorders is boosting the AATD augmentation therapy market in Asia-Pacific. Furthermore, improved diagnostic techniques for critical diseases is favoring expansion of the market in Asia-Pacific. Although Asia-Pacific exhibits highest CAGR, the AATD augmentation therapy market in North America was valued at US$ 620.0 Mn in 2018, which was the highest among all regions. The AATD augmentation therapy market in North America is likely to remain dominant throughout the forecast period. North America’s dominance is attributable to the rising prevalence of AATD disorder in the U.S. and Canada, and exceptional business strategies of leading companies in the region. Europe is estimated to be the second most prominent region in terms of market value in 2018.

Browse Complete Report Details @ https://www.fortunebusinessinsights.com/industry-reports/aatd-augmentation-therapy-100169

The global AATD augmentation therapy market is segmented based on: